文献速递神经技术与安全CTDSA

头部CT/CTA皮肤剂量实测与神经重症监护患者的累积暴露

Measured Head CT/CTA Skin Dose and Intensive Care Unit Patient Cumulative Exposure.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-01-19

前瞻性研究采用光激发光剂量计直接测量52例患者头部CT/CTA的峰值皮肤剂量,并与容积CT剂量指数比较;容积CT剂量指数高估峰值皮肤剂量1.4-1.9倍,4例神经重症监护患者多次检查的累积峰值皮肤剂量为1.9-4.5 Gy,可能超过单次确定性皮肤损伤阈值。

要点

  • 容积CT剂量指数高估头部CT/CTA峰值皮肤剂量1.4-1.9倍,不宜直接用于皮肤剂量评估。
  • 两台CT扫描仪患者实测峰值皮肤剂量与体模测量结果一致。
  • 神经重症监护患者多次头部CT/CTA累积剂量可达1.9-4.5 Gy,可能超过单次确定性皮肤损伤阈值。

核心结论

  • 直接测量的头部CT/CTA皮肤剂量明显低于容积CT剂量指数;实测峰值皮肤剂量证实,代表性神经重症监护患者多次头部CT/CTA检查可能产生超过单次确定性皮肤损伤阈值的累积剂量。

研究设计与样本

  • 2011-2013年前瞻性研究,52例患者(女28例、男24例,平均年龄63岁)均分于2台CT扫描仪,用nanoDot光激发光剂量计测量头部CT/CTA峰值皮肤剂量,并记录容积CT剂量指数和剂量长度乘积,另在丙烯酸颅骨体模上测量峰值皮肤剂量。

诊断标准与关键数值

  • 扫描仪1:患者头部CT峰值皮肤剂量39.2±3.7 mGy、CTA 98.9±5.3 mGy,体模分别为40.0 mGy和105.4 mGy。
  • 扫描仪2:患者头部CT峰值皮肤剂量42.9±9.4 mGy、CTA 98.8±7.4 mGy,体模分别为37.6 mGy和95.2 mGy。
  • 容积CT剂量指数高估峰值皮肤剂量1.4-1.9倍,倍数取决于检查类型和CT扫描仪。
  • 4例重症监护患者按实测峰值皮肤剂量估算的累积剂量为1.9-4.5 Gy。

临床应用与阅片要点

  • 头部CT/CTA皮肤剂量评估应以实测峰值皮肤剂量为准,容积CT剂量指数会高估1.4-1.9倍。
  • 神经重症监护患者多次头部CT/CTA检查时,应关注累积峰值皮肤剂量可能超过单次确定性皮肤损伤阈值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Estimates of cumulative CT/CTA radiation dose based on volumetric CT dose index have raised concern that neurological intensive care unit patient exposures may reach thresholds for deterministic skin injury. Because the accuracy of volumetric CT dose index for this purpose in unknown, we set out to directly measure head CT and CTA peak skin dose, assess the relationship of volumetric CT dose index to measured peak skin dose, and determine whether multiple CT/CTA exposures in typical patients in the neurological intensive care unit produce cumulative doses approaching or exceeding single-dose deterministic thresholds for skin injury.

MATERIALS AND METHODS: In a prospective study from 2011-2013, nanoDot optical stimulated luminescence dosimeters were used to measure head CT/CTA peak skin dose in 52 patients (28 female, 24 male; mean age, 63 years) divided equally between 2 CT scanners. Volumetric CT dose index and dose-length product were recorded for each examination. Peak skin dose was also measured on an acrylic skull phantom in each scanner. A 2-tailed, unpaired t test was used to compare mean patient skin doses between the 2 scanners. The measured peak skin doses were then used to calculate cumulative peak skin dose in 4 typical patients in intensive care units who received multiple CT/CTA scans.

RESULTS: Head CT/CTA peak skin dose agreed between scanners in patients and phantoms: (scanner 1 CT/CTA: patients, 39.2 ± 3.7 mGy and 98.9 ± 5.3 mGy, respectively, versus phantom, 40.0 mGy and 105.4 mGy, respectively; scanner 2 CT/CTA: patients, 42.9 ± 9.4 mGy and 98.8 ± 7.4 mGy, respectively, versus phantom, 37.6 mGy and 95.2 mGy, respectively). Volumetric CT dose index overestimated peak skin dose by a factor of 1.4-1.9 depending on examination and CT scanner. Cumulative doses in 4 patients in the intensive care unit estimated from measured CT/CTA peak skin dose ranged from 1.9-4.5 Gy.

CONCLUSIONS: Directly measured radiation skin doses from head CT/CTA patient examinations are substantially lower than volumetric CT dose index. Measured peak skin dose confirms that multiple head CT/CTA examinations in representative patients in the neurological intensive care unit may produce cumulative doses exceeding the single-dose deterministic threshold for skin injury.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Nawfel RD, Young GS. Measured Head CT/CTA Skin Dose and Intensive Care Unit Patient Cumulative Exposure. AJNR Am J Neuroradiol. 2017. PMID: 28104641. doi:10.3174/ajnr.A5040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。